Neumora Total Liab vs Net Working Capital Analysis
| NMRA Stock | 10.39 0.02 0.19% |
Neumora Therapeutics, financial indicator trend analysis is infinitely more than just investigating Neumora Therapeutics, recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Neumora Therapeutics, is a good investment. Please check the relationship between Neumora Therapeutics, Total Liab and its Net Working Capital accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neumora Therapeutics, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
Total Liab vs Net Working Capital
Total Liab vs Net Working Capital Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Neumora Therapeutics, Total Liab account and Net Working Capital. At this time, the significance of the direction appears to have strong relationship.
The correlation between Neumora Therapeutics,'s Total Liab and Net Working Capital is 0.66. Overlapping area represents the amount of variation of Total Liab that can explain the historical movement of Net Working Capital in the same time period over historical financial statements of Neumora Therapeutics, Common, assuming nothing else is changed. The correlation between historical values of Neumora Therapeutics,'s Total Liab and Net Working Capital is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Liab of Neumora Therapeutics, Common are associated (or correlated) with its Net Working Capital. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Working Capital has no effect on the direction of Total Liab i.e., Neumora Therapeutics,'s Total Liab and Net Working Capital go up and down completely randomly.
Correlation Coefficient | 0.66 |
| Relationship Direction | Positive |
| Relationship Strength | Significant |
Total Liab
The total amount of all liabilities that a company has, including both short-term and long-term liabilities.Net Working Capital
Most indicators from Neumora Therapeutics,'s fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Neumora Therapeutics, current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neumora Therapeutics, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. As of December 11, 2024, Selling General Administrative is expected to decline to about 30.1 M. In addition to that, Tax Provision is expected to decline to about 147.4 K
| 2021 | 2022 | 2023 | 2024 (projected) | Reconciled Depreciation | 538K | 594K | 668K | 523.9K | Total Operating Expenses | 237.3M | 135.9M | 187.5M | 180.5M |
Neumora Therapeutics, fundamental ratios Correlations
Click cells to compare fundamentals
Neumora Therapeutics, Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Neumora Therapeutics, offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Neumora Therapeutics,'s financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Neumora Therapeutics, Common Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Neumora Therapeutics, Common Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neumora Therapeutics, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neumora Therapeutics,. If investors know Neumora will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neumora Therapeutics, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.20) | Return On Assets (0.38) | Return On Equity (0.77) |
The market value of Neumora Therapeutics, is measured differently than its book value, which is the value of Neumora that is recorded on the company's balance sheet. Investors also form their own opinion of Neumora Therapeutics,'s value that differs from its market value or its book value, called intrinsic value, which is Neumora Therapeutics,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neumora Therapeutics,'s market value can be influenced by many factors that don't directly affect Neumora Therapeutics,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neumora Therapeutics,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Neumora Therapeutics, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neumora Therapeutics,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.